Implementing ADCC assays in QC: When donor variability isn’t an option
Supported by:
29 November 2017
ABOUT THIS WEBINAR:
Inherent donor variability of immune effector cells presents a significant challenge for developing a robust and reproducible ADCC assays for QC lot release. DiscoverX recently introduced the single donor-derived KILR CD16 Effector Cells to ensure assay reproducibility for screening, characterisation, and QC lot release of antibody drugs.
The webinar focused on 2 qualification studies that were performed using these effectors to demonstrate accuracy and precision in different assay formats.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Antibodies, Assays, Cell-based assays, cytotoxicity, Cytotoxicity assays, Immunoassays, Protein, Screening
Related organisations
Eurofins Discovery, Sartorius Stedim BioOutsource Limited
